$LXEO News

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Lexeo Therapeutics Q2 EPS $(0.30) Misses $(0.28) Estimate

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple

Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update?

Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript

JP Morgan Maintains Overweight on Lexeo Therapeutics, Lowers Price Target to $9

Lexeo Therapeutics's LX2006 Has A Viable Regulatory Pathway And Timeline

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Lexeo Therapeutics Reports Data For LX2006 Gene Therapy In Friedreich Ataxia, Pivotal SUNRISE-FA 2 Study On Track For 2026 Launch, Publishid In The JAMA Cardiology

Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript

Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call - Slideshow

Why Is Lexeo Therapeutics Stock Gaining Monday?

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

Lexeo Therapeutics Finalized SUNRISE-FA Pivotal Trial Protocol And Statistical Analysis Plan Intended To Provide Clinical Evidence To Support Submission FDA Application For Gene Therapy Candidate LX2006 Under The Accelerated Approval Pathway In 2028

Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Lexeo Therapeutics To Reveal Multiple Presentations At The 29th ASGCT Annual Meeting Taking Place May 11-15, 2026 In Boston, MA